Center of Oncocytogenetics Institute of Medical Biochemistry and Laboratory Diagnostics General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Centro Ricerca Tettamanti Clinica Pediatrica University of Milano Bicocca Monza Italy

Children's Cancer Institute Australia University of NSW Sydney Sydney Australia

Children's Cancer Research Institute Medical University of Vienna Vienna Austria

Clinic of Pediatric Hematology and Oncology University Medical Center Hamburg Eppendorf Hamburg Germany

CLIP Department of Paediatric Haematology Oncology Charles University Prague 2nd Faculty of Medicine Prague Czech Republic

DCAL Institute of Pharmaceutical Biology Goethe University Frankfurt Frankfurt am Main Germany

Department of Applied Bioinformatics Institute of Cell Biology and Neuroscience Goethe Universität Frankfurt Frankfurt am Main 60438 Germany

Department of Clinical Chemistry and Laboratory Division Turku University Hospital Turku Finland

Department of Cytogenetics Saint Louis Hospital Paris France

Department of Genetics AP HP Robert Debré Paris Diderot University Paris France

Department of Laboratory Medicine Inje University College of Medicine Busan Korea

Department of Pediatric Hematology Oncology Hemostaseology and Stem Cell Transplantation Dr von Hauner University Children's Hospital Ludwig Maximilian University Munich Munich Germany

Division of Clinical Research Research Center Instituto Nacional de Cancer Rio de Janeiro Brazil

Laboratoire d'Hématologie University Hospital Brest CHU de Bordeaux Bordeaux France

Murdoch Children's Research Institute The Royal Children's Hospital Flemington Road Parkville 3052 Victoria Australia

Pediatric Hematology Oncology Program Research Center Instituto Nacional de Cancer Rio de Janeiro Rio de Janeiro Brazil

Regional Children Hospital 1 Research Institute of Medical Cell Technologies Pediatric Oncology and Hematology Center Ural Federal University named after the first President of Russia BN Yeltsin Ekaterinburg Russia

Senckenberg Climate and Research Centre Frankfurt am Main 60325 Germany

Zobrazit více v PubMed

Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA. 2005;102:449–54. doi: 10.1073/pnas.0406994102. PubMed DOI PMC

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273–84. doi: 10.1038/leu.2017.213. PubMed DOI PMC

Zhang W, Sulea T, Tao L, Cui Q, Purisima EO, Vongsamphanh R, et al. Contribution of active site residues to substrate hydrolysis by USP2: insights into catalysis by ubiquitin specific proteases. Biochemistry. 2011;50:4775–85. doi: 10.1021/bi101958h. PubMed DOI

Nishi R, Wijnhoven P, le Sage C, Tjeertes J, Galanty Y, Forment JV, et al. Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity. Nat Cell Biol. 2014;16:1016–26. doi: 10.1038/ncb3028. PubMed DOI PMC

Clague MJ, Barsukov I, Coulson JM, Liu H, Rigden DJ, Urbé S. Deubiquitylases from genes to organism. Physiol Rev. 2013;93:1289–315. doi: 10.1152/physrev.00002.2013. PubMed DOI

Sacco JJ, Coulson JM, Clague MJ, Urbé S. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 2010;62:140–57. PubMed PMC

Wang J, Muntean AG, Hess JL. ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood. 2012;119:1151–61. doi: 10.1182/blood-2011-06-362079. PubMed DOI PMC

Wang J, Muntean AG, Wu L, Hess JL. A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity. J Biol Chem. 2012;287:43410–6. doi: 10.1074/jbc.M112.423855. PubMed DOI PMC

Muntean AG, Giannola D, Udager AM, Hess JL. The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood. 2008;112:4690–3. doi: 10.1182/blood-2008-01-134056. PubMed DOI PMC

Chen J, Santillan DA, Koonce M, Wei W, Luo R, Thirman MJ, et al. Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Cancer Res. 2008;68:6199–207. doi: 10.1158/0008-5472.CAN-07-6514. PubMed DOI PMC

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–15. doi: 10.1056/NEJMoa1403088. PubMed DOI PMC

Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. The genetic basis and cell of origin of mixed phenotype acute leukaemia. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47:330–7. doi: 10.1038/ng.3230. PubMed DOI PMC

Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562:373–9. doi: 10.1038/s41586-018-0436-0. PubMed DOI PMC

Peterson JF, Baughn LB, Pearce KE, Williamson CM, Benevides Demasi JC, Olson RM, et al. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. Genes Chromosomes Cancer. 2018;57:541–6. doi: 10.1002/gcc.22666. PubMed DOI

Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study

The KMT2A recombinome of acute leukemias in 2023

The Absence of Retroelement Activity Is Characteristic for Childhood Acute Leukemias and Adult Acute Lymphoblastic Leukemia